I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being transmitted via the Office electronic filing system in accordance with § 1.6(a)(4).

Dated: <u>December 31, 2007</u> Electronic Signature: <u>/Izumi Yokoyama, Ph.D./</u> (Izumi Yokoyama, Ph.D.)

Docket No.: L7350.0010 (PATENT)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Patent Application of: Tomohiko Ohta Confirmation No.: 1070

Application No.: 10/588,124 Art Unit: 1643

Filed: November 17, 2006 Examiner: A. M. Gussow

For: CARCINOSTATIC METHOD USING New York, NY

BRCA1-BARD1 PATHWAY December 31, 2007

RESPONSE TO RESTRICTION REQUIREMENT

MS Amendment

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Dear Sir:

The Office Action mailed October 10, 2007 (Paper No. 20071005) requires restriction to one of the following Groups for the present examination:

Group I, claim(s) 1-3, drawn to a method of polyubiquitinating a nucleophosmin;

Group II, claim(s) 4, and 7-9, drawn to a method of inhibiting polyubiquitination;

Group III, claim(s) 5 and 7-9, drawn to a method of degrading BRCA1-BARD;

Group IV, claim(s) 6 and 8-9, drawn to a method of inactivating ubiquitin ligase activity; and

Group V, claim(s) 10, drawn to a method of transporting BRCA1 from a nucleus to cytoplasm.

Application No.: 10/588,124 Docket No.: L7350.0010

Applicant hereby provisionally elects, without traverse, Group V (claim 10) drawn to a method of transporting BRCA 1 from a nucleus to cytoplasm, for the present examination.

Consideration of the present application in view of the above-election is respectfully requested.

Dated: <u>December 31, 2007</u> Respectfully submitted,

Electronic Signature: /Izumi Yokoyama, Ph.D./
Izumi Yokoyama, Ph.D.
Registration No.: 60,351
DICKSTEIN SHAPIRO LLP
1177 Avenue of the Americas
New York, New York 10036-2714

(212) 277-6500 Attorney for Applicant